BOSTON, Nov. 12, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), today announced that Thomson ONE initially reported understated Juniper results for the third quarter of 2015, including revenue, net income and EPS, on First Call, even though the Company accurately reported its third quarter 2015 financial results in its November 10, 2015 earnings press release.
The Company promptly notified Thomson ONE that they had understated its actual revenue, net income and EPS for the period, and Thomson ONE has corrected these errors.
For the quarter ended September 30, 2015, Juniper's actual total revenue was $11.5 million, net income was $1.0 million, and EPS was $0.09 per basic and diluted share.
"Thomson ONE corrected these errors on First Call at approximately 1:15pm today," said Frank Condella, Chief Executive Officer at Juniper Pharmaceuticals. "We ask websites, analysts, and others who rely on First Call's data to make certain that their reports and internal databases with respect to Juniper are based upon our accurately-reported third quarter financial results."
Juniper regularly reports its quarterly and annual results, and makes these results available through http://ir.juniperpharma.com/phoenix.zhtml?c=111526&p=irol-sec (SEC filings) and http://ir.juniperpharma.com/phoenix.zhtml?c=111526&p=irol-news&nyo=0 (press releases).
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. Juniper has a commercial product, CRINONE® 8% (progesterone gel), which is marketed by Allergan, Inc. in the U.S. and by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide. The Company is advancing a pipeline of proprietary drug candidates leveraging novel delivery technologies, including three novel intra-vaginal ring candidates announced at Juniper's 2015 Investor Day. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Allergan, Inc. in the U.S. and of Merck KGaA, Darmstadt, Germany, outside the U.S.
Forward Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are usually indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," or similar expressions, and which are generally not historical in nature. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law. For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2014.
Amy Raskopf Director, Corporate Communications Juniper Pharmaceuticals (917) 673-5775 email@example.com
Follow us on LinkedIn
SOURCE Juniper Pharmaceuticals, Inc.